Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
BioNTech SE
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
68High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07365995CT.gov A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT07005154CT.gov A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer | — | Recruiting | — | — | — |
NCT06764485CT.gov A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT07553988CT.gov A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT06320067CT.gov A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer | — | Recruiting | — | — | — |
NCT05489211CT.gov Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | — | Recruiting | — | — | — |
NCT03072238CT.gov Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT02074137CT.gov Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer | — | Completed | — | — | — |
NCT01972217CT.gov Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer. | — | Completed | — | — | — |
NCT05401214CT.gov Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination) | — | Approved For Marketing | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Prednisolone (this asset) | BioNTech SE | Approved | BB · 67 |
| AXUMIN | VA Greater Los Angeles Healthcare System | P4 | BBB |
| Leuporelin | Mayo Clinic | P4 | BBB |
| Abiraterone | Mayo Clinic | P4 | BB |
| Prednisone | Mayo Clinic | P4 | BB |
| Pembrolizumab | CuraCell TX AB | P2 | BB |
| Degarelix | Praful Ravi, MB BCHir, MRCP | P3 | BB |
| Carboplatin | Case Comprehensive Cancer Center | P3 | BB |
| Sipuleucel-T | Yale University | P2 | BB |
+42 more in the Metastatic Prostate Carcinoma cohort
Other indications for Prednisolone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Infantile Spasms | — | P4 | BBB · 79 |
| Non-Hodgkin Lymphoma | — | P3 | BBB · 74 |
| Lymphoma | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Prednisolone in Metastatic Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/prednisolone-metastatic-prostate-carcinoma-2003
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →